{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-24-000005","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.423815+00:00","generated_at":"2026-06-05T09:09:04.974842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M","bullets":["Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).","2024 global net product sales guidance of $310M to $320M, reflecting continued growth across approved medicines.","LIVMARLI PFIC PDUFA date on track for March 13, 2024; CHENODAL NDA for CTX planned H1 2024.","Volixibat VISTAS (PSC) and VANTAGE (PBC) interim analyses expected in first half 2024.","Appointed Joanne Quan, M.D. as Chief Medical Officer; cash and equivalents $286.3M as of Dec 31, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-24-000005","json":"https://secwatch.observer/filing/0001759425-24-000005.json","markdown":"https://secwatch.observer/filing/0001759425-24-000005.md","text":"https://secwatch.observer/filing/0001759425-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/0001759425-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/mirm-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T09:09:04.974842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"471c1afa0deaa9a1d3136ed2292cdf4829aa9ebe","claim":"Mirum Pharmaceuticals, Inc. updated its the quarter and year ended December 31, 2023 guidance (raised).","evidence_excerpt":"On February 28, 2024, Mirum Pharmaceuticals, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000175942524000005/0001759425-24-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}